Newborn screening for central congenital hypothyroidism: past, present and future
European Thyroid Journal · 01.02.2025 · 14 (1)
DOI: 10.1530/etj-24-0329 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Thyroid Journal, online erschienen am 06.02.2025. Verfasst von Mark R Garrelfs und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Endocrinology, Emma Children's Hospital, Amsterdam University Medical Centers, University of Amsterdam and Vrije Universiteit…. Hauptthemen laut MEDLINE: Congenital Hypothyroidism, Neonatal Screening. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Congenital hypothyroidism (CH) is defined as thyroid hormone deficiency at birth and constitutes one of the most common causes of preventable intellectual disability worldwide. Central CH is caused by insufficient pituitary or hypothalamic control of thyroid function, biochemically characterized by a low serum free thyroxine (fT4), in combination with a low, normal or mildly elevated thyroid-stimulating hormone (TSH). Central CH is less common than primary CH and is part of multiple pituitary hormone deficiencies (MPHD) in most of the cases. MPHD at birth, also known as ‘congenital hypopituitarism’, is a potentially life-threatening condition due to the possible co-occurrence of adrenocorticotropin hormone and growth hormone deficiency that can result in severe hypoglycemia and adrenal crisis. To date, central CH is the only pituitary hormone deficiency suitable for newborn screening (NBS), providing an opportunity for early detection of MPHD. Even though the first NBS programs utilized T4-based methods that were able to identify central CH, most countries have since transitioned to TSH-based approaches due to the high rate of false positives associated with T4-based strategies. Now, 50 years after the introduction of NBS for CH, only a few countries around the world have a screening program capable of detecting central CH. In this paper, we review the past, present and future of NBS for central CH. We will outline the importance of early detection of central CH and discuss the challenges and opportunities of screening for this condition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Endocrinology, Emma Children's Hospital, Amsterdam University Medical Centers, University of Amsterdam and Vrije Universiteit, European Reference Network on Rare Endocrine Conditions (Endo-ERN),…
- Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, The Netherlands.
- Endocrine Laboratory, Department of Laboratory Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
ORCID-Profile: Mark R Garrelfs, Christiaan F Mooij, Anita Boelen, A S Paul van Trotsenburg, Nitash Zwaveling-Soonawala
Zitieren
APA
Garrelfs, M. R., Mooij, C. F., Boelen, A., van Trotsenburg, A. S. P., & Zwaveling-Soonawala, N. (2025). Newborn screening for central congenital hypothyroidism: past, present and future. European Thyroid Journal, 14(1). https://doi.org/10.1530/etj-24-0329
Vancouver
Garrelfs MR, Mooij CF, Boelen A, van Trotsenburg ASP, Zwaveling-Soonawala N. Newborn screening for central congenital hypothyroidism: past, present and future. European Thyroid Journal. 2025;14(1). doi:10.1530/etj-24-0329
BibTeX
@article{Garrelfs2025,
author = {Garrelfs, Mark R and Mooij, Christiaan F and Boelen, Anita and van Trotsenburg, A S Paul and Zwaveling-Soonawala, Nitash},
title = {Newborn screening for central congenital hypothyroidism: past, present and future},
journal = {European Thyroid Journal},
year = {2025},
volume = {14},
number = {1},
doi = {10.1530/etj-24-0329}
}
EUVIMED